<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients (153) with biopsy-proven primary systemic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> (AL) were evaluated for their response rate to <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-based chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-seven of the patients (18%) responded </plain></SENT>
<SENT sid="2" pm="."><plain>The serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> concentration had an adverse effect on response rate (P = .05) </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo>, a <z:mpath ids='MPATH_458'>normal</z:mpath> serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> value, and no echocardiographic evidence of cardiac <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, the response rate was 39% (12 of 31) </plain></SENT>
<SENT sid="4" pm="."><plain>Five of 34 patients with amyloid <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> responded </plain></SENT>
<SENT sid="5" pm="."><plain>Two of these five are alive 10 years after diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>None of the 18 patients with amyloid <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> showed regression of their disease </plain></SENT>
<SENT sid="7" pm="."><plain>The median time to achieve response was 11.7 months </plain></SENT>
<SENT sid="8" pm="."><plain>The median survival of the 27 patients was 89.4 months and 21 of 27 survived 5 years (78%) </plain></SENT>
<SENT sid="9" pm="."><plain>Eight patients remain alive with a minimum follow-up of 90 months </plain></SENT>
<SENT sid="10" pm="."><plain>Seven died of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndrome</z:e>, a presumed complication of melphalan therapy </plain></SENT>
<SENT sid="11" pm="."><plain>In the group of 126 patients who showed no response to <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-based therapy, the median survival was 14.7 months and 9 (7%) survived over 5 years </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 126 patients have died </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="0" ids="22333">Alkylating agent</z:chebi>-based chemotherapy for AL is beneficial in a subset of patients and a trial of chemotherapy is strongly recommended </plain></SENT>
<SENT sid="14" pm="."><plain>Those patients who do respond demonstrate survival benefit </plain></SENT>
</text></document>